Apimeds Pharmaceuticals US, Inc. announced the expansion of its ai² Futures Lab™ program through a new collaboration with the University of Idaho College of Business and Economics, beginning in the Spring 2026 semester. The initiative connects student teams with real-world biopharma business development projects, reinforcing Apimeds’ commitment to fostering innovation, leadership, and discovery across the healthcare ecosystem.
Health Technology Insights: Health Technology Insights: Latest News And Innovations – Roundup 4 November 2025
The ai² Futures Lab™ functions as both a discovery engine for potential therapeutic assets and a training ground for the next generation of biotech and business leaders. Through this collaboration, University of Idaho students will work alongside Apimeds mentors to evaluate early-stage pharmaceutical assets, perform market and IP analysis, and identify novel strategies to improve patient care and expand therapeutic opportunities.
“We’re thrilled to bring the ai² Futures Lab to the University of Idaho,” said Brian Peters, SVP of the ai² Division at Apimeds Pharmaceuticals. “This program is designed to spark real innovation by connecting bright, ambitious students with real-world biotech challenges. The entrepreneurial spirit and collaborative culture at Idaho align perfectly with our mission to blend business acumen and scientific insight into actionable solutions for patients.”
Health Technology Insights: Mirum Pharma showcases LIVMARLI and Volixibat data at AASLD
Mark Groza, Director of Distance Education and Professor of Marketing at the University of Idaho College of Business and Economics, added: “By strengthening our partnerships with industry and providing experiential learning opportunities for our MBA students, this collaboration directly supports the University of Idaho’s land-grant mission and core pillars of our strategic plan. It gives our students a front-row seat to where business strategy, science, and innovation intersect. Working with Apimeds allows them to apply classroom concepts in a high-impact, hands-on environment and will help prepare them to lead in emerging sectors such as biotechnology and healthcare.”
Erik Emerson, CEO of Apimeds Pharmaceuticals, emphasized the growing reach of the ai² Futures Lab initiative: “The expansion of ai² Futures Lab into Idaho marks another important milestone in building an ecosystem where education and innovation meet. Each new partnership strengthens our ability to cultivate fresh perspectives, inspire future leaders, and accelerate discovery in meaningful ways.”
The University of Idaho joins the University of Alabama, University of San Diego and the University of Oregon as part of the expanding ai² Futures Lab™ network — a cornerstone of Apimeds’ ai² innovation platform, which integrates actual intelligence (the power of human insight) with AI-driven analytics to uncover transformative opportunities in biotechnology and beyond.
Health Technology Insights: Gilead’s Livdelzi Shows ALP Reduction and Itch Relief in PBC
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
Source – businesswire
